Welcome to our dedicated page for Avalon Globocare SEC filings (Ticker: ALBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalon GloboCare Corp. filings document public-company disclosures for its consumer diagnostics, generative AI software, intellectual property, and capital structure. Recent 8-K reports cover material events involving Avalon Quantum AI LLC, the Catch-Up AI video platform, Nasdaq listing-compliance notices, shareholder communications, and pro forma financial information tied to the completed sale of Avalon RT 9 Properties, LLC.
The company’s proxy and registration filings describe board elections, auditor ratification, equity incentive-plan matters, advisory compensation votes, Nasdaq-rule approvals for warrant share issuance, and securities registration matters. Avalon’s filings also address common stock, warrants, pre-funded warrants, shareholder voting mechanics, governance procedures, operating and financial results, and risk disclosures for a smaller reporting company.
Avalon GloboCare Corp. (ALBT) reported continued operating losses and significant balance sheet activity in the six months ended June 30, 2025. The company recorded recurring net losses of approximately $15.94 million for the six-month period and generated negative operating cash flow of about $3.03 million. During Q1 2025 Avalon completed the redemption of its 40% equity interest in Lab Services MSO for aggregate cash of $1.745 million and the surrender of Series B preferred stock (carrying value $11.0 million), recognizing an increase to additional paid-in capital of $2.3487 million. The company recorded a $9.0766 million loss on extinguishment of debt related to modification/waiver of the June 2024 convertible note financing. Derivative liabilities declined, producing a fair value gain of $446,816 for the six months. The company wrote off and reserved for credit losses ($1.65 million) and reported material warrant and convertible instruments, including the June 2024 convertible note (principal $2.845 million). Avalon’s laboratory services segment ceased upon the Lab Services MSO redemption; the real property segment remains operational.
Avalon GloboCare Corp. issued 221,000 shares of unregistered common stock to a noteholder upon partial conversions of an outstanding promissory note between July 30, 2025 and August 6, 2025. After these issuances the company reported 3,690,109 shares outstanding as of August 6, 2025. The filing states the shares were not registered under the Securities Act and were offered in reliance on the Section 4(a)(2) exemption.
The disclosure provides the exact share amount and updated share count but contains no details on the promissory note balance converted, the conversion price, or any cash impacts. The information is factual and narrow in scope, limited to the share issuance and the registration exemption relied upon.
Avalon GloboCare Corp. (Nasdaq: ALBT) filed a Form 8-K dated 28 Jul 2025 to disclose that its wholly-owned subsidiary, Q&A Distribution, LLC, has entered a distribution agreement with Saga Health Corporation for the KetoAir™ breathalyzer device. The filing is made under Item 7.01 (Reg FD) and includes the related press release as Exhibit 99.1.
No financial terms, volume commitments or revenue projections were provided. Management expressly states the information is furnished, not filed, thereby avoiding automatic incorporation into other SEC documents. While the agreement could broaden ALBT’s presence in the metabolic health diagnostics market, investors have insufficient data to quantify potential sales or profitability impact. No other material events, financial statements, or pro-forma data accompany this report.
Avalon GloboCare (Nasdaq: ALBT) filed an 8-K disclosing a definitive agreement dated June 23 2025 with subsidiary Q&A Distribution and Qi Diagnostics to co-develop a volatile-organic-compound breathalyzer for THC screening.
The four-stage project requires Q&A to fund up to $975,000 in milestone payments: $95k (stage 1), $180k (stage 2), $300k (stage 3) and $400k (stage 4).
In return, Q&A earns a passive financial interest in the resulting intellectual property, escalating from 6% after milestone 1 to 50% if all milestones are met; Qi Diagnostics retains operational control of the IP.
Either party may terminate on 30-days notice, but vested IP interests survive. No revenue projections, regulatory approvals or guidance were provided. Exhibits 10.1 and 99.1 contain the full agreement and press release.